Triple-combination therapy with metformin, DPP4 inhibitors, and SGLT2 inhibitors can target multiple pathophysiological pathways for T2DM, affecting at least six of eight components in the “ominous octet” [22], and appears to strike an appropriate balance among efficacy, safety, and tolerability profiles. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.